ArticleComputational and structural biotechnology reports2025
Molecular mechanisms underlying enhanced ACE-2-RBD stability in SARS-CoV-2 variants: The impact of key SARS-CoV-2 RBD mutations.
Article in Computational and structural biotechnology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Viruses undergo mutations over time, most of which have little to no impact. However, certain changes can significantly influence viral traits such as transmissibility and disease severity. Newer SARS-CoV-2 variants, including XBB.1.5, XBB.1.16, EG.5, and BA.2.86, have emerged with key mutations-D405N, G446S, N460K, and R408S-altering their biological behavior. This study explores how mutations in the receptor-binding domain (RBD) of various SARS-CoV-2 variants affect their molecular interactions, structural stability, and binding affinity with the human ACE-2 receptor (hACE-2), offering insights valuable for drug discovery. Using computational methods, binding free energy calculations revealed that variants such as BQ.1.1, CH.1.1, EG.5, EG.5.1, XBB.1, XBB.1.5, XBB.1.9.1, XBB.2.3, and BA.2.75 demonstrate stronger binding to hACE-2 than the wild-type (WT), which exhibited a binding energy of -35.24 ± 8.97 kcal/mol. This enhanced binding is linked to increased hydrogen bonds (H-bonds) and electrostatic interactions, with correlation coefficients of 0.51 and 0.28, respectively. Structural stability analyses, based on average RMSD values, showed that most mutations did not compromise the RBD-hACE-2 complex's integrity, except in variants XBB.1.5, XBB.1.9.1, and XBB.1.9.2. These findings suggest that specific mutations enhance interactions through H-bonds, hydrophobic effects, and electrostatic forces, contributing to overall stability. In summary, this study highlights that several SARS-CoV-2 variants bind more effectively to hACE-2 than the WT and earlier variants like BA.5 and BQ.1. These stronger interactions may underlie their higher transmission rates. The molecular insights provided here improve understanding of how specific mutations influence the virus's behavior, aiding future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.